comparemela.com

Latest Breaking News On - Exxel pharma - Page 1 : comparemela.com

Exxel Pharma, Inc : Exxel Pharma to Participate in the Virtual Investor Lunch Break: The Exxel Opportunity

Exxel Pharma, Inc : Exxel Pharma to Participate in the Virtual Investor Lunch Break: The Exxel Opportunity
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Exxel pharmaSoren mogelsvangJenene thomasExxel pharma incChief executive officerVirtual investor lunch breakExxel opportunityCarsten stork

Exxel Pharma to Participate in the Virtual Investor Lunch Break: The Exxel Opportunity

Live webcast with Soren Mogelsvang, PhD, Chief Executive Officer of Exxel Pharma, on Wednesday, May 8th at 12 PM ETAURORA, CO / ACCESSWIRE / May 1, 2024 / Exxel Pharma ("Exxel" or the "Company"), an early-stage pharma company working to develop EX937 as a safe and effective treatment for patients.

Exxel pharmaSoren mogelsvangJenene thomasExxel pharma incChief executive officerVirtual investor lunch breakExxel opportunity

Exxel Pharma to Participate in the Virtual Investor Lunch Break: The Exxel Opportunity

Exxel Pharma to Participate in the Virtual Investor Lunch Break: The Exxel Opportunity
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.

Jenene thomasSoren mogelsvangExxel pharmaExxel pharma incChief executive officerVirtual investor lunch breakExxel opportunity

Exxel Pharma Provides Business Overview and Upcoming Milestones

Exxel Pharma Provides Business Overview and Upcoming Milestones

Exxel pharmaSoren mogelsvangKey programJenene thomaschief executive officerjtc teamNews networkCompany on linkedinExxel pharma incChief executive officerProgram highlightsFast track designation demonstratedExpected upcoming milestones

Exxel Pharma Provides Business Overview and Upcoming Milestones

Company advancing innovative, small molecule for treatment of refractory chronic cough where there are currently no FDA-approved therapies Lead program, EX937, initially targeting a $11B global market with potential to expand into multiple high-value indications Differentiated approach with demonstrated preclinical.

Exxel pharmaSoren mogelsvangJenene thomasKey programExxel pharma incCompany on linkedinChief executive officerFast track

vimarsana © 2020. All Rights Reserved.